Okay, let's tackle this question about the treatment of varicella in an immunocompetent host. First, I need to recall the core concept here. Varicella, or chickenpox, is a viral infection caused by the varicella-zoster virus (VZV). In immunocompetent individuals, the treatment is usually supportive because the immune system can handle the infection without severe complications.

The correct answer is likely an antiviral medication, but I need to remember which one is recommended. Acyclovir is commonly used for VZV. But wait, there's also valacyclovir and famciclovir. However, acyclovir is the standard for varicella, especially when given within 24 hours of rash onset. It's important to note that in immunocompetent hosts, antivirals are sometimes not given because the disease is self-limiting, but if there's a risk of complications, they might be prescribed.

Now, looking at the options, the correct answer would be acyclovir. Let me check why the other options are wrong. If the options included other antivirals like ganciclovir or foscarnet, those are used for CMV, not VZV. Alternatively, if the options had antibiotics like amoxicillin, that's incorrect because varicella is viral. Corticosteroids would be contraindicated here as they can worsen viral infections.

The clinical pearl here is that antiviral therapy is most effective when started early. Also, in immunocompetent patients, the mainstay is supportive care with antivirals reserved for high-risk groups. The high-yield fact is the timing of acyclovir administration—within 24 hours of rash onset.

**Core Concept**
Varicella (chickenpox) caused by varicella-zoster virus (VZV) is typically self-limiting in immunocompetent hosts. Treatment focuses on **supportive care** and **antiviral therapy** to reduce complications like secondary bacterial infections or disseminated disease. Acyclovir is the first-line antiviral due to its efficacy against VZV.

**Why the Correct Answer is Right**
Acyclovir is a nucleoside analog that inhibits VZV DNA synthesis by targeting viral thymidine kinase. In immunocompetent patients, it is recommended for high-risk individuals (e.g., adolescents, adults) or when administered within **24 hours of rash onset** to shorten duration and severity. It reduces viral shedding and complications like pneumonia or encephalitis.

**Why Each Wrong Option is Incorrect**
**Option A:** Ganciclovir targets CMV, not VZV, and lacks activity against thymidine kinase in VZV.
**Option B:** Valacyclovir is a prodrug of acyclovir with better bioavailability but is not first-line for varicella due to cost and similar efficacy.
**Option D:** Foscarnet inhibits viral DNA polymerase but is reserved for acyclovir-resistant VZV infections or immunocompromised patients.

**Clinical Pearl / High-Yield Fact**
**Start acyclovir within 24 hours of rash onset** in high-risk immunocompetent hosts. Avoid

✓ Correct Answer: C. Prevention of complications